FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Company Summary - Yidu Tech (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Yidu Tech achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's "2025 Artificial Intelligence Medical Device Innovation Task" list with a multimodal AI database project for gastrointestinal tumor diagnosis in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting that 2026 will likely see greater certainty in AI medical commercialization and open up new commercial opportunities [1][1][1] - Key areas to focus on include AI pharmaceuticals, grassroots AI medical applications, medical data circulation and trading, AI pathological diagnosis, AI medical models, and C-end expansion channels, along with related targets [1][1][1]

Company Summary - Medicure Technology (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Medicure Technology achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's 2025 AI medical device innovation project list with a multimodal AI database project for gastrointestinal tumor diagnosis and treatment in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting a stronger certainty for AI medical commercialization in 2026 [1][1][1] - Key areas for investment focus include AI drug development, grassroots AI medical applications, medical data circulation and trading, AI pathology diagnosis, AI medical models, and C-end expansion channels [1][1][1]

医渡科技(02158)发布公告，于2026年2月11日斥资290.62万港元回购48.6万股。 ...

格隆汇2月11日丨医渡科技(02158.HK)公告，2月11日耗资290.6万港元回购48.6万股。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月11日斥资290.62万港元回购48.6万股。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

格隆汇2月10日丨医渡科技(02158.HK)公告，2月10日耗资1万港元回购1700股。 ...

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的 ...

Market Overview - The Hong Kong stock market showed initial gains but narrowed its increase, with the Hang Seng Index closing up 0.58% above 27,000 points, while the Hang Seng China Enterprises Index and Hang Seng Tech Index rose by 0.81% and 0.62% respectively [1][2]. Sector Performance - Technology stocks rebounded, driven by AI application stocks, with the stock of Reading Group surging over 15%. The film and entertainment sector remained active, and the biopharmaceutical sector saw widespread gains, led by Fuhong Hanlin [3][4]. - New consumption concept stocks, paper industry stocks, home appliance stocks, shipping stocks, and automotive stocks mostly increased. Conversely, education stocks faced declines, with gaming stocks collectively sluggish, and real estate, gas, electric, and telecom stocks also underperformed [3][4]. Notable Stocks - AI application stocks saw significant gains, with Reading Group rising 15.41%, and Zhiyun up 14.81%, reaching a new historical high during the session. Other stocks like Fubo Group and Yidu Technology also experienced increases [6][8]. - In the film sector, Orange Sky Entertainment rose over 7%, with other companies like Damai Entertainment and Ningmeng Film also following suit [10]. - The biopharmaceutical sector was buoyed by Fuhong Hanlin's increase of over 7%, with other companies like WuXi Biologics and WuXi AppTec also seeing gains [12]. Industry Insights - The real estate sector faced pressure, with Shimao Group dropping over 6% amid ongoing sales challenges in the industry. Major real estate companies are reportedly initiating organizational restructuring [13][14]. - Education stocks struggled, with Guangzheng Education falling over 5%, alongside declines in New Oriental and other educational institutions [15]. Investment Outlook - According to Everbright Securities, the current liquidity environment in the Hong Kong stock market is entering an observation period, with limited space for further tightening. Positive catalysts could lead to a recovery in market sentiment and capital inflow [22].